Everyone is talking about the recent peptide updates, but has anything actually changed? In this episode, Partner Samuel Pondrom breaks down the latest recommendations from the FDA advisory committee involving six popular peptides (BPC-157, KPV, TB-500, MOTS-C, Epitalon, and Semax). Learn why these recommendations are only one step in the regulatory process, and why state law, patient-specific prescriptions, reliable sourcing, and accurate marketing still matter. Discover how practices navigate emerging peptide services without mistaking regulatory movement for a green light.
Chapters
00:00 Intro
01:42 Banter
04:43 Story
26:09 Access+
26:48 Legal Takeaways
30:28 Outro
Watch full episodes of our podcast on our YouTube channel: https://www.youtube.com/@byrdadatto
Stay connected for the latest business and health care legal updates:
Website
Facebook
Instagram
LinkedIn